We identified miR-525-5p and HIF-1α as the negative and positive regulator in FGF11-dependent function, suggesting that targeting these molecules can serve as novel therapeutic approaches for treating NSCLC. The gene discussed is FGF11; the disease is non-small cell lung carcinoma.